Key result
HbA1c ≥9% plus elevated LDL-C is linked to ~2.8-fold higher diabetic neuropathy risk.
Why the study?
Neuropathy is highly prevalent with a poor prognosis in patients with T2DM, and while HbA1c has a limited regulatory role, the role of LDL-C and their joint association with diabetic neuropathy remained unclear.
Does poor glycemic control (HbA1c ≥7%) alone or jointly with suboptimal LDL-C (≥2.6 mmol/L) increase the risk of developing diabetic neuropathy in patients with type 2 diabetes mellitus?
Cohort (n=1,484)
Yes
Does poor glycemic control (HbA1c ≥7%) alone or jointly with suboptimal LDL-C (≥2.6 mmol/L) increase the risk of developing diabetic neuropathy in patients with type 2 diabetes mellitus?
Answers are grounded in this paper and cite their sources.
HbA1c is a strong independent risk factor for type 2 diabetic neuropathy whereas elevated LDL-C alone is not, though poor glycemic control in patients with suboptimal LDL-C (≥2.6 mmol/L) confers a markedly elevated risk of neuropathy.
Neuropathy is highly prevalent and has a poor prognosis in type 2 diabetes mellitus (T2DM) patients. T2DM is accompanied by abnormal glucose and lipid metabolism. Glycated haemoglobin (HbA1c) is a risk factor with a limited regulatory role. The role of low-density lipoprotein cholesterol (LDL-C) also remains unclear. Here, we analysed the effects of HbA1c and LDL-C on type 2 diabetic neuropathy. Patients with T2DM with no baseline neuropathy were selected from the UK Biobank (UKB) database; 1,484 patients were enrolled based on a 12-year follow-up period. Patients were grouped according to their HbA1c levels(< 7%, 7–9%, and ≥ 9%) and their LDL-C levels (< 2.6 mmol/L and ≥ 2.6 mmol/L). Cox regression analysis revealed associations between HbA1c and LDL-C levels and the risk of type 2 diabetic neuropathy. Next, logistic regression was performed using clinical data from 611 patients with T2DM. We also analysed the interaction between LDL-C and HbA1c. After adjustment for confounding factors, compared with HbA1c < 7%, both HbA1c 7–9% and ≥ 9% were associated with an increased risk of type 2 diabetic neuropathy [HR = 1.62 (1.31–2.01); P < 0.001; HR = 2.44 (1.76–3.38); P < 0.001] in the UKB; compared with LDL-C < 2.6 mmol/L, LDL-C ≥ 2.6 mmol/L did not increase the risk of type 2 diabetic neuropathy [HR = 1.06(0.81–1.40); P = 0.675]. Compared with LDL-C ≥ 2.6 mmol/L combined with HbA1c < 7%, LDL-C ≥ 2.6 mmol/L combined with HbA1c ≥ 9% increased the risk of type 2 diabetic neuropathy [HR = 2.80 (1.76–4.48); P < 0.001]. Consistent findings were observed in the logistic regression analysis of clinical data and in sex-stratified analyses. HbA1c is an independent risk factor for neuropathy in patients with T2DM. LDL-C is not associated with type 2 diabetic neuropathy. However, in the context of suboptimal LDL-C control, extremely poor HbA1c control is closely associated with diabetic neuropathy than well controlled HbA1c.
No takes yet. Share an insight, caveat, or question.
Lv et al. (2026) conducted a cohort in Type 2 diabetes mellitus (n=1,484). Elevated HbA1c (≥9%) combined with elevated LDL-C (≥2.6 mmol/L) vs. Well-controlled HbA1c (<7%) combined with LDL-C ≥2.6 mmol/L was evaluated on Incident type 2 diabetic neuropathy (defined by ICD-10 code E114 in UK Biobank) (HR 2.80, 95% CI 1.76-4.48, p=<0.001). Extremely poor glycemic control combined with LDL-C ≥2.6 mmol/L increased the risk of type 2 diabetic neuropathy compared to HbA1c <7%.
Synapse has enriched 10 related papers. Consider them for comparative context: